The SIRT 3 Expression Profile is Associated with Pathological and Clinical Outcomes in Human Breast Cancer Patients

被引:28
作者
He, Shaozhong [1 ,2 ]
He, Chun [2 ]
Yuan, Hua [1 ]
Xiong, Shizhong [2 ]
Xiao, Zhenyu [2 ]
Chen, Longhua [1 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China
[2] Peoples Hosp Ganzhou, Dept Oncol, Ganzhou, Peoples R China
关键词
SIRT; 3; Breast cancer; Clinical characteristics; Prognosis; CARCINOMA IN-SITU; RISK-FACTORS; DUCTAL CARCINOMA; PROGNOSIS; CARDIOMYOPATHY; SURVIVAL; THERAPY; ALPHA;
D O I
10.1159/000366401
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: To investigate the association of Sirtuin 3 (SIRT 3) expression between the clinical characteristics and prognosis in breast cancer patients. Methods: 308 female patients with histologically confirmed breast cancer were enrolled in this study. The SIRT 3 expressions in tumor samples were detected. All the patients were followed up overall survival time (OS) and disease-free survival (DFS) time. Results: SIRT 3 expression was significantly correlated with clinical characteristics including lymph node metastasis, pathological grade and tumor size of breast cancer. SIRT 3 expression status also affected the DFS and OS of breast cancer. Patients with high expression of SIRT 3 had shorter DFS and OS than those with low expression. Univariate and multivariate Cox analyses confirmed that high SIRT 3 expression predicted a poor prognosis in breast cancer patient. In vitro study revealed that the SIRT 3 knockdown by small interfering RNA technique dramatically reduced the proliferation, migration and invasion of breast cancer cell lines. Conclusion: Our results suggest that SIRT 3 may serve as a marker for clinical feature and prognosis for breast cancer. Copyright (C) 2014 S. Karger AG, Basel
引用
收藏
页码:2061 / 2069
页数:9
相关论文
共 33 条
  • [1] SIRT3 and cancer: Tumor promoter or suppressor?
    Alhazzazi, Turki Y.
    Kamarajan, Pachiyappan
    Verdin, Eric
    Kapila, Yvonne L.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2011, 1816 (01): : 80 - 88
  • [2] Sirtuin-3 (SIRT3), a Novel Potential Therapeutic Target for Oral Cancer
    Alhazzazi, Turki Y.
    Kamarajan, Pachiyappan
    Joo, Nam
    Huang, Jing-Yi
    Verdin, Eric
    D'Silva, Nisha J.
    Kapila, Yvonne L.
    [J]. CANCER, 2011, 117 (08) : 1670 - 1678
  • [3] Altered sirtuin expression is associated with node-positive breast cancer
    Ashraf, N.
    Zino, S.
    MacIntyre, A.
    Kingsmore, D.
    Payne, A. P.
    George, W. D.
    Shiels, P. G.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (08) : 1056 - 1061
  • [4] Outcome of Pure Mucinous Breast Carcinoma Compared to Infiltrating Ductal Carcinoma: A Population-based Study from China
    Cao, A-Yong
    He, Min
    Liu, Zhe-Bin
    Di, Gen-Hong
    Wu, Jiong
    Lu, Jin-Song
    Liu, Guang-Yu
    Shen, Zhen-Zhou
    Shao, Zhi-Ming
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (09) : 3019 - 3027
  • [5] Chen Ling, 2007, Chinese Journal of Pathology, V36, P228
  • [6] Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer
    Desouki, Mohamed Mokhtar
    Doubinskaia, Irina
    Gius, David
    Abdulkadir, Sarki A.
    [J]. HUMAN PATHOLOGY, 2014, 45 (05) : 1071 - 1077
  • [7] SIRT1 Is Essential for Oncogenic Signaling by Estrogen/Estrogen Receptor α in Breast Cancer
    Elangovan, Selvakumar
    Ramachandran, Sabarish
    Venkatesan, Narayanan
    Ananth, Sudha
    Gnana-Prakasam, Jaya P.
    Martin, Pamela M.
    Browning, Darren D.
    Schoenlein, Patricia V.
    Prasad, Puttur D.
    Ganapathy, Vadivel
    Thangaraju, Muthusamy
    [J]. CANCER RESEARCH, 2011, 71 (21) : 6654 - 6664
  • [8] Engel J, 2001, STRAHLENTHER ONKOL, V177, P371
  • [9] Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China
    Fan, Lei
    Zheng, Ying
    Yu, Ke-Da
    Liu, Guang-Yu
    Wu, Jiong
    Lu, Jin-Song
    Shen, Kun-Wei
    Shen, Zhen-Zhou
    Shao, Zhi-Ming
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 117 (02) : 409 - 416
  • [10] Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bNOMO): A review of the literature
    Hanrahan, EO
    Valero, V
    Gonzalez-Angulo, AM
    Hortobagyi, GN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) : 2113 - 2122